Eli Lilly disclosed additional safety and tolerability data on retatrutide, including arrhythmia and major cardiovascular event rates, as the company continues to position its next-generation obesity franchise. The figures were shared alongside efficacy context from TRANSCEND-T2D-1 at the American Diabetes Association meeting and published in The Lancet, sharpening the risk lens for further development.